07:00 , Aug 14, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Lactadherin (MFGE8; HMFG) Studies in patient samples and cell culture suggest inhibiting MFGE8 could help...
08:00 , Feb 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Lactadherin (MFGE8; HMFG); integrin aVb5; integrin aVb3 (CD51/CD61) Mouse studies...
08:00 , Feb 13, 2014 |  BC Innovations  |  Cover Story

Curb your fatty acids

A University of California, San Francisco team has uncovered a pathway for regulating absorption of fatty acids that could yield new targets for treating obesity. MFGE8, an integrin ligand, controls the uptake of fat in...
08:00 , Jan 24, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Lactadherin (MFGE8; HMFG) Mouse studies suggest increasing MFGE8 levels could help...
07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Lactadherin (MFGE8; HMFG) Mouse studies suggest inhibiting MFGE8 could help decrease chemotherapy resistance. Tumor-associated macrophages in...
08:00 , Nov 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Pulmonary fibrosis Lactadherin...
07:00 , Jun 4, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...
08:00 , Feb 2, 2009 |  BC Week In Review  |  Clinical News

Access Pharmaceuticals preclinical data

In mouse xenograft models of breast cancer, Angiolix significantly inhibited tumor growth. Additionally, the activity of the humanized IgG1k mAb that binds to Lactadherin was enhanced when given in combination with chemotherapy. The efficacy...
07:00 , Jun 30, 2008 |  BC Week In Review  |  Clinical News

Access Pharmaceuticals preclinical data

Using in vitro and mouse xenograft models, Angiolix blocked new blood vessel formation in tumors. The antibody against lactadherin is in preclinical testing as monotherapy and in combination with other angiogenesis inhibitors. Data were...
07:00 , Sep 10, 2007 |  BC Week In Review  |  Clinical News

Access Pharmaceuticals, Somanta preclinical data

In mouse models of ovarian cancer, Angiolix localized to the cancer and did not affect normal tissues. Angiolix is a humanized monoclonal antibody that binds to lactadherin. SMPM is being acquired by ACCP (see...